A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

NCT00401362

Last updated date
Study Location
Progenics Pharmaceuticals, Inc.
Tarrytown, New York, 10591, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Illness Patients With Opioid Induced Constipation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Advanced medical illness with a life expectancy of 1 to 6 months

2. No clinically significant laxation within 48 hours prior to the first dose of study drug

3. On stable opioid and laxative regimen for a least 3 days prior to treatment

4. Age greater than 18years

5. Females of child-bearing age must have a negative pregnancy test.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Females who are pregnant or nursing.


2. Previous treatment with MNTX or prior treatment with naltrexone or naloxone for
treatment of OIC


3. Any disease process suggestive of gastrointestinal obstruction


4. Fecal ostomy.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Advanced Illness Patients With Opioid Induced ConstipationA a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients
NCT00401362
  1. Tarrytown, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients
Official Title  ICMJE A Double-Blind Placebo-Controlled Study of Methylnaltrexone (MNTX) for the Relief of Constipation Due to Chronic Opioid Therapy in Patients With Advanced Medical Illness
Brief Summary To test the effectiveness of MNTX in advanced illness subjects.
Detailed Description To determine the efficacy of MNTX compared to placebo to induce laxation in patients receiving opioids.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Advanced Illness Patients With Opioid Induced Constipation
Intervention  ICMJE
  • Drug: SC Methylnaltrexone
    Dose 1
  • Drug: SC Placebo
  • Drug: SC Methylnaltrexone
    Dose 2
Study Arms  ICMJE
  • Experimental: Arm 1
    Intervention: Drug: SC Methylnaltrexone
  • Placebo Comparator: Arm 3
    Intervention: Drug: SC Placebo
  • Experimental: Arm 2
    Intervention: Drug: SC Methylnaltrexone
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 31, 2011)
154
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE February 2005
Actual Primary Completion Date February 2005   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Advanced medical illness with a life expectancy of 1 to 6 months
  2. No clinically significant laxation within 48 hours prior to the first dose of study drug
  3. On stable opioid and laxative regimen for a least 3 days prior to treatment
  4. Age greater than 18years
  5. Females of child-bearing age must have a negative pregnancy test.

Exclusion Criteria:

  1. Females who are pregnant or nursing.
  2. Previous treatment with MNTX or prior treatment with naltrexone or naloxone for treatment of OIC
  3. Any disease process suggestive of gastrointestinal obstruction
  4. Fecal ostomy.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00401362
Other Study ID Numbers  ICMJE MNTX 301
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Tage Ramakrishna, MD, Progenics Pharmaceuticals, Inc.
Study Sponsor  ICMJE Bausch Health Americas, Inc.
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Director:Tage Ramakrishna, MDProgenics Pharmaceuticals, Inc.
PRS Account Bausch Health Americas, Inc.
Verification Date November 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP